Announcements Trials
Browse Landscape

Phase

Phase 2 55Phase 1 10Phase NA 9Phase 1/2 8Phase 3 3Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Plasma cell 1Lymphoid 1

Conditions

Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Lymphoid 1Hematologic Neoplasms 1

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 10Zoledronic Acid 8ixazomib 4daratumumab 4Thalidomide 4Melphalan 4Cyclophosphamide 4tocilizumab 3Prednisone 3pomalidomide 2carfilzomib 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1fludarabine phosphate 1fludarabine 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Busulfan × Plasma cell × Clear all
NCT00361140 2017-03-03

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

H. Lee Moffitt Cancer Center and Research Institute

Phase 4 Completed
72 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoid, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡